Utility of PREDICT-HF score in high-risk Asian heart failure patients receiving sacubitril/valsartan

Chien Yi Hsu, Hung Yu Chang, Chieh Ju Chao, Wei Ru Chiou, Po Lin Lin, Fa Po Chung, Wen Yu Lin, Jin Long Huang, Huai Wen Liang, Chia Te Liao, Ying Hsiang Lee

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)


Objective: The aim of this study was to investigate the application of sacubitril/valsartan in clinical practice and the utility of PREDICT-HF score for outcome prediction in Asian heart failure patients with difference risk profiles. Methods: The TAROT-HF study was a multicenter, single-arm, observational study. Totally 1,187 outpatients with HFrEF treated with sacubitril/valsartan were enrolled and categorized by: (1) high-risk group with ≥1 of the following three risk factors: old age (≥80 years), low baseline systolic blood pressure (<100 mmHg), and renal impairment (eGFR <30 ml/min/1.73 m2), and (2) standard-risk group, those who did not have any risk factors. Clinical outcomes were assessed using the PREDICT-HF risk model. Results: A total of 305 (25.7%) patients matched the criteria for the high-risk group. The event rates of cardiovascular death or first unplanned heart failure hospitalization (HFH) among the overall population, high-risk, and standard-risk groups were 13.7, 24.9, and 10.8 events per 100 patient-years, respectively. The C statistics for the PREDICT-HF model in the overall cohort and high-risk group for cardiovascular death or first unplanned HFH at 2 years were 0.73 (95% CI 0.70–0.76) and 0.71 (95% CI 0.65–0.76), respectively. The permanent discontinuation rate among the high-risk patients was significantly higher than that among the standard-risk patients (8.3 vs. 2.5 per 100 patient-years, p < 0.001). Conclusions: Real-world outcomes of the TAROT-HF study demonstrated that the PREDICT-HF model performed well in Asian HFrEF patients. Three easily detected clinical profiles of age, renal function, and systolic BP could help to identify patients at risk before initiating sacubitril/valsartan.

Original languageEnglish
Article number950389
JournalFrontiers in Cardiovascular Medicine
Publication statusPublished - Jul 25 2022


  • heart failure
  • high-risk population
  • PREDICT-HF model
  • sacubitril/valsartan

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Utility of PREDICT-HF score in high-risk Asian heart failure patients receiving sacubitril/valsartan'. Together they form a unique fingerprint.

Cite this